Drugs / DN1508052-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03934359 | Sep 2019 → Aug 2022 | cancer | Shanghai De Novo Pharmatech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DN1508052-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03934359 ↗ |
| Route | Subcutaneous | “will be administered subcutaneously” NCT03934359 ↗ |